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Need an add-on to metformin? 
Consider this
Sulfonylureas have been the preferred add-on therapy to 
metformin for T2DM, but a study finds that DPP-4s have 
lower risks of death, CV events, and hypoglycemia. 
PRACTICE CHANGER
Consider a dipeptidyl peptidase-4 inhibitor 
before a sulfonylurea for patients with type 2 
diabetes mellitus who require therapy in 
addition to metformin. 
Ou SM, Shih CJ, Chao PW, et al. Effects of clinical outcomes of add-
ing dipeptidyl peptidase-4 inhibitors versus sulfonylureas to metfor-
min therapy in patients with type 2 diabetes mellitus. Ann Intern Med. 
2015;163:663-672.1
STRENGTH OF RECOMMENDATION
B: Based on limited-quality, patient-oriented 
data from a high-quality, population-based 
cohort study.
ILLUSTRATIVE CASE
A 58-year-old woman with type 2 diabetes 
mellitus (T2DM) and heart failure returns to 
your office for follow-up of her T2DM. She 
has been on the maximum dose of metformin 
alone for the past 6 months, but her HbA1c 
is now 7.8%. She is keen to avoid injections. 
What do you recommend next?
There is surprisingly little consen-sus about what to add to metfor-min for patients with T2DM who 
require a second agent to achieve their 
glycemic goal. Attainment of glycemic con-
trol earlier in the course of the disease 
may lead to reduced overall cardiovascu-
lar risk, so the choice of a second drug is an 
important one.2 While metformin is well 
established as initial pharmacotherapy 
because of its proven mortality benefit, wide 
availability, and low cost, no second-choice 
drug has amassed enough evidence of benefit 
to emerge as the add-on therapy of choice. 
Furthermore, the professional societ-
ies and associations are of little assistance. 
Dual therapy recommendations from the 
American Diabetes Association (ADA) and 
the European Association for the Study of 
Diabetes do not denote a specific preference, 
and while the American Association of Clini-
cal Endocrinologists/American College of 
Endocrinology do suggest a hierarchy of 
choices, it is based upon expert consensus 
recommendation.3,4
Sulfonylureas can cause  
hypoglycemia and weight gain
Options for add-on therapy include sulfonyl-
ureas, thiazolidines, dipeptidyl peptidase-4 
(DPP-4) inhibitors, sodium glucose cotrans-
porter 2 (SGLT2) inhibitors, glucagon-like 
peptide 1 (GLP-1) agonists, and insulin. 
Providers have frequently prescribed a sul-
fonylurea after metformin because such 
agents are low in cost, have long-term safety 
data, and are effective at lowering HbA1c. 
Sulfonylureas work by directly stimulating 
insulin secretion by pancreatic beta cells 
in a glucose-independent manner. But as a 
2010 meta-analysis revealed, they carry sig-
nificant risks of hypoglycemia (relative risk 
[RR]=4.57; 95% confidence interval [CI], 2.11-
11.45) and weight gain (2.06 kg; 95% CI, 1.15-
2.96) compared to placebo.5 
DPP-4 inhibitors, on the other hand, 
work by inducing insulin secretion in a glu-
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cose-dependent manner through an incre-
tin mechanism. Combined with metformin, 
they provide glucose control similar to that 
achieved with the combination of a sulfonyl-
urea and metformin.6 DPP-4 inhibitors were 
initially found to be associated with fewer 
cardiovascular events and less hypoglycemia 
than sulfonylureas, but were subsequently 
linked to an increased risk of hospitalization 
for heart failure.7 
This latest large observational study pro-
vides more evidence on the effects of DPP-4s 
when added to metformin.1
STUDY SUMMARY
DPP-4s as effective as sulfonylureas  
with no increased risks
This population-based observational cohort 
study compared DPP-4 inhibitors and sul-
fonylureas when added to metformin for 
the treatment of T2DM.1 Outcomes were 
all-cause mortality, major adverse car-
diovascular events (MACEs; defined as 
hospitalization for ischemic stroke or 
myocardial infarction [MI]), and hospital-
izations for either heart failure or hypogly-
cemia. Using the National Health Insurance 
Research Database in Taiwan, the study 
included data on over 70,000 patients ages 
20 years and older with a diagnosis of T2DM. 
Individuals adherent to metformin were con-
sidered to be enrolled into the cohort on the 
day they began using either a DPP-4 inhibitor 
or a sulfonylurea, in addition to metformin.
The researchers collected additional 
data on the enrolled individuals regarding 
socioeconomic factors, urbanization, robust-
ness of the local health care system, Charlson 
Comorbidity Index, adapted Diabetes Com-
plications Severity Index, and other comor-
bidities and medications that could affect 
the outcomes of interest. Using these data, 
enrollees were matched by propensity score 
into 10,089 pairs consisting of a DPP-4 inhibi-
tor user and a sulfonylurea user.
After a mean follow-up period of 
2.8 years, the authors of the study used Cox 
regression analysis to evaluate the relative 
hazards of the outcomes. Subgroup analysis 
performed by age, sex, Charlson Comorbid-
ity Index, hypertension, chronic kidney dis-
ease, hospitalization for heart failure, MI, and 
cerebrovascular disease yielded results simi-
lar to those of the primary analysis for each 
outcome. Additionally, similar results were 
obtained when the data were analyzed with-
out propensity-score matching. 
❚ The researchers found that users of 
DPP-4 inhibitors—when compared to users 
of sulfonylureas—had a lower risk of all-cause 
mortality (366 vs 488 deaths; hazard ratio 
[HR]=0.63; 95% CI, 0.55-0.72; number needed 
to treat [NNT]=117), MACE (209 vs 282 events; 
HR=0.68; 95% CI, 0.55-0.83; NNT=191), isch-
emic stroke (144 vs 203 strokes; HR 0.64; 95% 
CI, 0.51-0.81; NNT=246), and hypoglycemia 
(89 vs 170 events; HR=0.43; 95% CI, 0.33-0.56; 
NNT=201). Further, there were no signifi-
cant differences in either the number of MIs 
that occurred (69 vs 88 MIs; HR=0.75; 95% 
CI, 0.52-1.07) or in the number of hospital-
izations for heart failure (100 vs 100 events; 
HR=0.78; 95% CI, 0.57-1.06) between users of 
DPP-4 inhibitors and those of sulfonylureas.
WHAT’S NEW
Lower risks of death,  
CV events, and hypoglycemia 
This study found that when added to met-
formin, DPP-4 inhibitors were associated 
with lower risks for all-cause mortality, car-
diovascular events, and hypoglycemia when 
compared to sulfonylureas. Additionally, 
DPP-4 inhibitors did not increase the risk 
of hospitalization for heart failure. A recent 
multicenter observational study of nearly 
1.5 million patients on the effects of incre-
tin-based treatments, including both DPP-4 
inhibitors and GLP-1 agonists, similarly 
found no increased risk of hospitalization for 
heart failure, with DPP-4 inhibitors compared 
to other combinations of oral T2DM agents.8
CAVEATS
Did unmeasured confounders  
play a role?  
Unmeasured confounders potentially bias all 
observational population cohort results. In 
this study, in particular, there may have been 
unmeasured, but significant, patient factors 
that providers used to choose diabetes medi-
Combined  
with metformin, 
DPP-4s provide 
glucose control 
similar to that 
achieved with 
the combination 
of a sulfonylurea 
and metformin. 
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Use of DPP-4s  
appears to have 
a lower risk  
of all-cause  
mortality,  
major adverse 
cardiovascular 
events, ischemic 
stroke, and 
hypoglycemia, 
compared to use 
of sulfonylureas.
cations. Also, the study did not evaluate dia-
betes control, although previous studies have 
shown similar glucose control between sul-
fonylureas and DPP-4 inhibitors when they 
were added to metformin.6 
Another caveat is that the results from 
this study group may not be fully general-
izable to other populations due to physi-
ologic differences. People of Asian ancestry 
are at risk of developing T2DM at a lower 
body mass index than people of European 
ancestry, which could affect the outcomes of 
interest.9 
Furthermore, the study did not evaluate 
outcomes based on whether patients were 
taking first-, second-, or third-generation sul-
fonylureas. Some sulfonylureas, such as gly-
buride, carry a higher risk of hypoglycemia, 
which could bias the results if a large number 
of patients were taking them.10 
Lastly, the study only provides guid-
ance when choosing between a sulfonylurea 
and a DPP-4 inhibitor for second-line phar-
macotherapy. The GRADE trial, due to be 
completed in 2023, is comparing sulfonyl-
ureas, DPP-4 inhibitors, GLP-1 agonists, and 
insulin as add-on medications to metformin, 
and may provide more data on which to base 
treatment decisions.11 
CHALLENGES TO IMPLEMENTATION
DPP-4s have a higher price tag  
than sulfonylureas
Sulfonylureas and DPP-4 inhibitors are both 
available as generic medications, but the 
cost of DPP-4 inhibitors remains significantly 
higher.12 Higher copays and deductibles 
could affect patient preference. Furthermore, 
for patients without health insurance, sulfo-
nylureas are available on the discounted drug 
lists of many major retailers, while DPP-4 
inhibitors are not.                  JFP
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